Cytochrome P450 2W1 (CYP2W1) – ready for use as the biomarker and drug target for cancer?

References

• Aung P, Oue N, Mitani Y, et al. (2006). Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 25:2546–57.
   PubMed Web of Science ®Google Scholar
• Bauer T, Bouman HJ, van Werkum JW, et al. (2011). Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343:d4588.
   PubMed Web of Science ®Google Scholar
• Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. (1998). Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase. Adv Enzyme Regul 38:111–33.
   PubMedGoogle Scholar
• Black SD. (1992). Membrane topology of the mammalian P450 cytochromes. FASEB J 6:680–5.
   PubMed Web of Science ®Google Scholar
• Bozina N, Bradamante V, Lovrić M. (2009). Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 60:217–42.
   PubMed Web of Science ®Google Scholar
• Cárdenas-Rodírguez N, Lara-Padilla E, Bandala C, et al. (2012). CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in mexican women with breast cancer. Asian Paci J Cancer Prev 13:837–46.
   PubMedGoogle Scholar
• Carrière V, Chambaz J, Rousset M. (2001). Intestinal responses to xenobiotics. Toxicol In Vitro 15:373–8.
   PubMed Web of Science ®Google Scholar
• Cervinski MA, Schwab MC, Lefferts JA, et al. (2013). Establishment of a CYP2C19 genotyping assay for clinical use. Am J Clin Pathol 139:202–7.
   PubMed Web of Science ®Google Scholar
• Choong E, Guo J, Persson A, et al. (2015). Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumours. PLoS One 10:1–17.
   Web of Science ®Google Scholar
• Choudhary D, Jansson I, Stoilov I, et al. (2005). Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys 436:50–61.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, McKeigue PM, Smith GD. (2003). Problems of reporting genetic associations with complex outcomes. Lancet 361:865–72.
   PubMed Web of Science ®Google Scholar
• Cui J, Meng Q, Zhang X, et al. (2015). Design and synthesis of new α-naphthoflavones as cytochrome P450 (CYP) 1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression. J Med Chem 58:3534–47.
   PubMed Web of Science ®Google Scholar
• Ding X, Kaminsky L. (2003). Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal. Annu Rev Pharmacol Toxicol 43:149–73.
   PubMed Web of Science ®Google Scholar
• Du L, Hoffman SMG, Keeney DS. (2004). Epidermal CYP2 family cytochromes P450. Toxicol Appl Pharmacol 195:278–87.
   PubMed Web of Science ®Google Scholar
• Eberl HC, Mann M, Vermeulen M. (2011). Quantitative proteomics for epigenetics. Chembiochem 12:224–34.
   PubMed Web of Science ®Google Scholar
• Edler D, Stenstedt K, Öhrling K, et al. (2009). The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer – A pilot study. Eur J Cancer 45:705–12.
   PubMed Web of Science ®Google Scholar
• Elingarami S, Liu H, Kalinjuma AV, et al. (2015). Polymorphisms in NEIL-2, APE-1, CYP2E1 and MDM2 genes are independent predictors of gastric cancer risk in a Northern Jiangsu population (China). J Nanosci Nanotechnol 15:4815–28.
   PubMed Web of Science ®Google Scholar
• Van Emburgh BO, Hu JJ, Levine EA, et al. (2008). Polymorphisms in CYP1B1, GSTM1, GSTT1 and GSTP1, and susceptibility to breast cancer. Oncol Rep 19:1311–21.
   PubMed Web of Science ®Google Scholar
• Eun CY, Han S, Lim YR, et al. (2013). Bioactivation of aromatic amines by human CYP2W1, an orphan cytochrome P450 enzyme. Toxicol Res 26:171–5.
   Google Scholar
• Fanni D, Ambu R, Gerosa C, et al. (2014). Cytochrome P450 genetic polymorphism in neonatal drug metabolism: role and practical consequences towards a new drug culture in neonatology. Int J Immunopathol Pharmacol 27:5–13.
   PubMed Web of Science ®Google Scholar
• Fei-Lei Chung F, Wai Mai C, Yuen Ng P, Leong CO. (2015). Cytochrome P450 2W1 (CYP2W1) in colorectal cancers. Curr Cancer Drug Targets 16:71–8.
   Web of Science ®Google Scholar
• Gervasini G, de Murillo SG, Ladero JM, Agúndez JAG. (2010). CYP2W1 variant alleles in Caucasians and association of the CYP2W1 G541A (Ala181Thr) polymorphism with increased colorectal cancer risk. Pharmacogenomics 11:919–25.
   PubMed Web of Science ®Google Scholar
• Girault I, Rougier N, Chesné C, et al. (2005). Simultaneous measurement of 23 isoforms from the human cytochrome P450 families 1 to 3 by quantitative reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 33:1803–10.
   PubMed Web of Science ®Google Scholar
• Gomez A, Karlgren M, Edler D, et al. (2007). Expression of CYP2W1 in colon tumours: regulation by gene methylation. Pharmacogenomics 8:1315–25.
   PubMed Web of Science ®Google Scholar
• Gomez A, Nekvindova J, Travica S, et al. (2010). Colorectal cancer-specific cytochrome P450 2W1: intracellular localisation, glycosylation, and catalytic activity. Mol Pharmacol 78:1004–11.
   PubMed Web of Science ®Google Scholar
• Gotoh O. (2012). Evolution of cytochrome P450 genes from the viewpoint of genome informatics. Biol Pharm Bull 35:812–17.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Ryan DP, Boyajian R, et al. (2005). Unexpected association between induction of immunity to the universal tumour antigen CYP1B1 and response to next therapy. Clin Cancer Res 11:4430–6.
   PubMed Web of Science ®Google Scholar
• Gröer C, Busch D, Patrzyk M, et al. (2014). Journal of Pharmaceutical and Biomedical Analysis Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics. J Pharm Biomed Anal 100:393–401.
   PubMed Web of Science ®Google Scholar
• Guo J, Johansson I, Mkrtchian S, Ingelman-Sundberg M. (2016). The CYP2W1 enzyme: regulation, properties and activation of prodrugs. Drug Metab Rev 48:1–10.
   Web of Science ®Google Scholar
• Guo J, Thiess S, Johansson I, et al. (2016). Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1. FEBS Lett 590:330–9.
   PubMed Web of Science ®Google Scholar
• Hanzawa Y, Sasaki T, Mizugaki M, et al. (2008). Genetic polymorphisms and haplotype structures of the human CYP2W1 gene in a Japanese population. Drug Metab Dispos 36:349–52.
   PubMed Web of Science ®Google Scholar
• Hartanto F, Karen-Ng L, Vincent-Chong V, et al. (2015). KRT13, FAIM2 and CYP2W1 mRNA expression in oral squamous cell carcinoma patients with risk habits. Asian Pac J Cancer Prev 16: 953–8.
   PubMedGoogle Scholar
• Ju W, Yang S, Ansede JH, et al. (2014). CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement. J Pharm Sci 103:337–49.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Gomez A, Stark K, et al. (2006). Tumour-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341:451–8.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Miura SI, Ingelman-Sundberg M. (2005). Novel extrahepatic cytochrome P450s. Toxicol Appl Pharmacol 207:57–61.
   PubMedGoogle Scholar
• Kawakami H, Ohtsuki S, Kamiie J, et al. (2011). Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 100:341–52.
   PubMed Web of Science ®Google Scholar
• Lalani AS, Alters SE, Wong A, et al. (2007). Selective tumour targeting by the hypoxia-activated prodrug AQ4N blocks tumour growth and metastasis in preclinical models of pancreatic cancer. Clin Cancer Res 13:2216–25.
   PubMed Web of Science ®Google Scholar
• Langenfeld E, Zanger UM, Jung K, et al. (2009). Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. Proteomics 9:2313–23.
   PubMed Web of Science ®Google Scholar
• Leong CO, Tan BS, Tiong KH, et al. (2011). Abstract C75: CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 10:C75.
   Web of Science ®Google Scholar
• Li W, Tang Y, Hoshino T, Neya S. (2009). Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. J Mol Graph Model 28:170–176.
   PubMed Web of Science ®Google Scholar
• Lowenthal RM, Eaton K. (1996). Toxicity of chemotherapy. Hematol/Oncol Clin North Am 10:967–90.
   PubMed Web of Science ®Google Scholar
• Martin FL, Patel II, Sozeri O, et al. (2010). Constitutive expression of bioactivating enzymes in normal human prostate suggests a capability to activate pro-carcinogens to DNA-damaging metabolites. The Prostate 70:1586–99.
   PubMed Web of Science ®Google Scholar
• McFadyen MC, McLeod HL, Jackson FC, et al. (2001). Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62:207–12.
   PubMed Web of Science ®Google Scholar
• McFadyen MCE, Murray GI. (2005). Cytochrome P450 1B1: a novel anticancer therapeutic target. Future Oncol 1:259–63.
   PubMedGoogle Scholar
• Meunier V, Bourrié M, Berger Y, Fabre G. (1995). The human intestinal epithelial cell line Caco-2; pharmacological and pharmacokinetic applications. Cell Biol Toxicol 11:187–194.
   PubMed Web of Science ®Google Scholar
• Molina-Ortiz D, Camacho-Carranza R, González-Zamora JF, et al. (2014). Differential expression of Cytochrome P450 enzymes in normal and tumour tissues from childhood rhabdomyosarcoma. PLoS One 9:e93261.
   PubMed Web of Science ®Google Scholar
• Molina-Ortiz D, González-Zamora JF, Camacho-Carranza R, et al. (2013). Xenobiotic-metabolizing enzymes in skeletal muscle of children and adolescents. Pharmacol Pharm 4:231–239.
   Google Scholar
• Mortimer CG, Wells G, Crochard JP, et al. (2006). Antitumor benzothiazoles. 26.1 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a simple fluorinated 2-arylbenzothiazole, shows potent and selective inhibitory activity against lung, colon, and breast cancer cell lines. J Med Chem 49:179–85.
   PubMed Web of Science ®Google Scholar
• Nebert DW, Dalton TP. (2006). The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6:947–960.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SMG, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18.
   PubMedGoogle Scholar
• Nielsen T, Knutz PC, Kuijpers A. (2008). Seismic Expression of contourite depositional system. Dev sedimentol 60:301–321.
   Google Scholar
• Nishida CR, Lee M, de Montellano PRO. (2010). Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78:497–502.
   PubMed Web of Science ®Google Scholar
• O'Hurley G, Sjöstedt E, Rahman A, et al. (2014). Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol 8:783–98.
   PubMed Web of Science ®Google Scholar
• Ong CE, Pan Y, Mak JW, Ismail R. (2013). In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability. Expert Opin Drug Metab Toxicol 9:1097–113.
   PubMed Web of Science ®Google Scholar
• Patterson LH, McKeown SR. (2000). AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83:1589–93.
   PubMed Web of Science ®Google Scholar
• Pors K, Loadman PM, Shnyder SD, et al. (2011). Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. Chem Commun 47:12062–4.
   PubMed Web of Science ®Google Scholar
• Qi GZ, Wang X, Miao XJ, et al. (2015). Novel single nucleotide polymorphisms (SNPs) of CYP2W1 gene in Chinese Uygur and Han populations. Drug Metab Pharmacokinet 30:449–52.
   PubMed Web of Science ®Google Scholar
• Raleigh SM, Wanogho E, Burke MD, et al. (1998). Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 42:763–767.
   PubMed Web of Science ®Google Scholar
• Renaud HJ, Cui JY, Khan M, Klaassen CD. (2011). Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci 124:261–77.
   PubMed Web of Science ®Google Scholar
• Rochat B, Morsman JM, Murray GI, et al. (2001). Human CYP1B1 and anticancer agent metabolism: mechanism for tumour-specific drug inactivation? J Pharm Exp Ther 296:537–41.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Sbiera S, Volante M, et al. (2014). CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. PLoS One 9:e105855.
   PubMed Web of Science ®Google Scholar
• Sheldrake HM, Travica S, Johansson I, et al. (2013). Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity. J Med Chem 56:6273–7.
   PubMed Web of Science ®Google Scholar
• Shrivas K, Mindaye ST, Getie-Kebtie M, Alterman MA. (2013). Mass spectrometry-based proteomic analysis of human liver cytochrome (s) P450. Toxicol Appl Pharmacol 267:125–136.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Blunt NJ, Desnoyers R, et al. (1997). DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 39:455–61.
   PubMed Web of Science ®Google Scholar
• Spink DC, Spink BC, Cao JQ, et al. (1997). Induction of cytochrome P450 1B1 and catechol oestrogen metabolism in ACHN human renal adenocarcinoma cells. J Steroid Biochem Mol Biol 62:223–32.
   PubMed Web of Science ®Google Scholar
• Stenstedt K. (2013). CYP2W1 in colorectal cancer – aspects of risk, prognosis and future treatment options. Doctoral dissertation. Sweden: Karolinska Institutet. Retrieved from: https://openarchive.ki.se/xmlui/handle/10616/41779.
   Google Scholar
• Stenstedt K, Hallstrom M, Johansson I, et al. (2012). The expression of CYP2W1: a prognostic marker in colon cancer. Anticancer Res 32: 3869–74.
   PubMed Web of Science ®Google Scholar
• Stenstedt K, Hallstrom M, Lédel F, et al. (2014). The expression of CYP2W1 in colorectal primary tumours, corresponding lymph node metastases and liver metastases. Acta Oncol 53:885–91.
   PubMed Web of Science ®Google Scholar
• Stenstedt K, Travica S, Guo J, et al. (2013). CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer. Pharmacogenomics 14:1615–22.
   PubMed Web of Science ®Google Scholar
• Sutherland M, Gill JH, Loadman PM, et al. (2013). Antitumor activity of a duocarmycin analogue rationalised to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther 12:27–37.
   PubMed Web of Science ®Google Scholar
• Sutter TR, Tang YM, Hayes CL, et al. (1994). Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem 269:13092–9.
   PubMed Web of Science ®Google Scholar
• Sutton CW, Sutherland M, Shnyder S, Patterson LH. (2010). Improved preparation and detection of cytochrome P450 isoforms using MS methods. Proteomics 10:327–331.
   PubMed Web of Science ®Google Scholar
• Travica S. 2013. Cytochrome P450 2W1 (CYP2W1) as a novel drug target in colon cancer therapy [unpublished doctoral dissertation]. Stockholm, Sweden: Karolinska Institutet.
   Google Scholar
• Travica S, Pors K, Loadman PM, et al. (2013). Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumour cytotoxins. Clin Cancer Res 19:2952–61.
   PubMed Web of Science ®Google Scholar
• Wang K, Guengerich FP. (2012). Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1. Chem Res Toxicol 25:1740–1751.
   PubMed Web of Science ®Google Scholar
• Wu ZL, Sohl CD, Shimada T, Guengerich FP. (2006). Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69:2007–14.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Guengerich FP. (2012). Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J Lipid Res 53:1610–17.
   PubMed Web of Science ®Google Scholar
• Xie YQ, Chen JM, Liu Y. (2016). Interaction of the CYP1A1 gene polymorphism and smoking in non-small cell lung cancer susceptibility. Genet Mol Res 14:19411–17.
   PubMed Web of Science ®Google Scholar
• Yakkundi A, McErlane V, Murray M, et al. (2006). Tumour-selective drug activation: a GDEPT approach utilising cytochrome P450 1A1 and AQ4N. Cancer Gene Ther 13:598–605.
   PubMed Web of Science ®Google Scholar
• Yasuzawa T, Murol KI, Ichimura M, et al. (1995). Duocarmycins, potent antitumor antibiotics produced by Streptomyces sp. structures and chemistry. Chem Pharm Bull 43:378–91.
   Google Scholar
• Yoshioka H, Kasai N, Ikushiro S, et al. (2006). Enzymatic properties of human CYP2W1 expressed in Escherichia coli. Biochem Biophys Res Commun 345:169–174.
   PubMed Web of Science ®Google Scholar
• Zhang K, Jiang L, He R, et al. (2014). Prognostic value of CYP2W1 expression in patients with human hepatocellular carcinoma. Tumour Biol 35:7669–73.
   PubMed Web of Science ®Google Scholar
• Zhao XD, Dong N, Man HT, et al. (2013). Antiproliferative effect of the Ginkgo biloba extract is associated with the enhancement of cytochrome P450 1B1 expression in oestrogen receptor-negative breast cancer cells. Biomed Rep 1:797–801.
   PubMedGoogle Scholar
• Zhao Y, Wan D, Yang J, et al. (2016). Catalytic activities of tumour-specific human cytochrome P450 CYP2W1 towards endogenous substrates. Drug Metab Dispos 44:771–80.
   PubMed Web of Science ®Google Scholar